3.97

1.48% 0.08

Dare Bioscience Inc (DARE)

Overview News Price History Financials Discussions Forecast Stock Split

Dare Bioscience Inc stock is traded at $3.97, with a volume of 12,920. It is up +1.48% in the last 24 hours and up +22.24% over the past month. Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Previous Close:

$3.89

Open:

$3.88

24h Volume:

12,920

Relative Volume:

0.32

Market Cap:

$32.22M

Revenue:

Net Income/Loss:

$-30.16M

P/E Ratio:

-8.6304

EPS:

-0.46

Net Cash Flow:

$-39.49M

1W Performance:

-0.32%

1M Performance:

+22.24%

6M Performance:

+1,168%

1Y Performance:

+917.13%

1-Day Range:

$3.76

$3.95

1-Week Range:

$3.76

$4.28

52-Week Range:

$0.27

$4.28

Dare Bioscience Inc Stock (DARE) Company Profile

Name

Dare Bioscience Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

858-926-7655

Address

3655 NOBEL DRIVE, SAN DIEGO, CA

Employee

Twitter

@DareBioscience

Next Earnings Date

2024-11-07

Latest SEC Filings

DARE's Discussions on Twitter

Dare Bioscience Inc Stock (DARE) Latest News

Oct 30, 2024

Dare BioscienceCatering To Women - RTTNews

Oct 30, 2024

Is Bavarian Nordic (BVNRY) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Oct 30, 2024

Oct 28, 2024

Dare Bioscience shares retain Buy rating on funding reward By Investing.com - Investing.com Canada

Oct 24, 2024

Oct 23, 2024

Dare Bioscience awarded $10M for HPV treatment development - Investing.com India

Oct 23, 2024

Dare Bioscience awarded $10M for HPV treatment development By Investing.com - Investing.com South Africa

Oct 23, 2024

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health - The Bakersfield Californian

Oct 23, 2024

Daré Bioscience Enters Purchase Agreement with Lincoln Park Capital Fund - Defense World

Oct 23, 2024

Oct 21, 2024

Dare Bioscience secures $15 million funding agreement By Investing.com - Investing.com Australia

Oct 21, 2024

Dare Bioscience secures $15 million funding agreement - Investing.com

Oct 21, 2024

Daré Bioscience Announces Common Stock Purchase Agreement - GlobeNewswire

Oct 21, 2024

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC - StockTitan

Oct 21, 2024

Oct 04, 2024

Brookline Capital Downgrades Daré Bioscience (DARE) - MSN

Oct 04, 2024

Sep 26, 2024

Bill Gates helped fund birth control microchip but didn't invent it | Fact check - USA TODAY

Sep 26, 2024

Sep 24, 2024

Dye & Durham Limited - Baystreet.ca

Sep 24, 2024

Sep 23, 2024

DADA’s 2023 Market Dance: Down -64.46% – Time to Invest? - The InvestChronicle

Sep 23, 2024

Sep 22, 2024

Barrow Hanley Mewhinney & Strauss LLC Raises Stake in Darling Ingredients Inc. (NYSE:DAR) - Defense World

Sep 22, 2024

Darling Ingredients Inc. (NYSE:DAR) Shares Sold by Meiji Yasuda Asset Management Co Ltd. - Defense World

Sep 22, 2024

Sep 21, 2024

MDA Space shares target raised on Telesat Lightspeed deals By Investing.com - Investing.com Australia

Sep 21, 2024

Sep 19, 2024

The Dare Announce 2024 Australian Headlining Shows - Music Feeds

Sep 19, 2024

Sep 18, 2024

The Dare Shares Inaugural Australian Tour Dates - The Music

Sep 18, 2024

ADMA Biologics stock soars to all-time high of $19.36 - Investing.com

Sep 18, 2024

Sep 16, 2024

The massive, untapped opportunity in women’s health - BioWorld Online

Sep 16, 2024

Sep 14, 2024

Daré Bioscience (NASDAQ:DARE) Share Price Crosses Below Two Hundred Day Moving Average of $4.51 - Defense World

Sep 14, 2024

Sep 06, 2024

Daré Bioscience (NASDAQ:DARE) Stock Price Passes Below Two Hundred Day Moving Average of $4.59 - Defense World

Sep 06, 2024

Sep 02, 2024

Its Stock Has Paid Off Big Time For Dare Bioscience Inc - SETE News

Sep 02, 2024

Aug 26, 2024

Daré Bioscience Announces Publication in The Journal of - GlobeNewswire

Aug 26, 2024

Sildenafil cream shows promise for FSAD without common side effects - Investing.com

Aug 26, 2024

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% - StockTitan

Aug 26, 2024

Aug 24, 2024

Daré Bioscience (NASDAQ:DARE) Shares Pass Below Two Hundred Day Moving Average of $4.62 - Defense World

Aug 24, 2024

Aug 17, 2024

Daré Bioscience, Inc. (NASDAQ:DARE) to Post FY2024 Earnings of ($0.33) Per Share, Brookline Capital Management Forecasts - Defense World

Aug 17, 2024

Aug 16, 2024

HC Wainwright Comments on Daré Bioscience, Inc.’s Q3 2024 Earnings (NASDAQ:DARE) - Defense World

Aug 16, 2024

Maxim Group Reiterates “Hold” Rating for Daré Bioscience (NASDAQ:DARE) - Defense World

Aug 16, 2024

Aug 14, 2024

Sildenafil Cream study suggests simplified patient reporting - Investing.com

Aug 14, 2024

Aug 13, 2024

Sildenafil Cream study suggests simplified patient reporting By Investing.com - Investing.com Canada

Aug 13, 2024